MPI 5003

Drug Profile

MPI 5003

Alternative Names: AccuSite; Fluorouracil/epinephrine injectable gel

Latest Information Update: 24 Jun 1999

Price : $50

At a glance

  • Originator Chiron Corporation
  • Developer ALTANA Group; Chiron Corporation; Dompe; Savage Laboratories
  • Class
  • Mechanism of Action Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Market Withdrawal Human papillomavirus infections
  • Discontinued Basal cell cancer; Kaposi's sarcoma; Psoriasis; Squamous cell cancer

Most Recent Events

  • 24 Jun 1999 Withdrawn for Human papillomavirus infections in United Kingdom (Intralesional)
  • 24 Jun 1999 Discontinued-III for Basal cell cancer in European Union (Intralesional)
  • 24 Jun 1999 Discontinued-II for Squamous cell cancer in Australia (Intralesional)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top